TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation
Brief Summary: The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A):

1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and
2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.


Options:
A: Intervention Type: DRUG; Name: Angiomax (bivalirudin) anticoagulant; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: systematic coronary intervention | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: coronary intervention only for cases refractory to medical therapy | Intervention Type: OTHER; Name: systematic coronary intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: coronary intervention only for cases refractory to medical therapy; Assigned to Arm(s): 2
C: Arm Label: Immediate Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Selective invasive angiography; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Intervention Type: PROCEDURE; Name: Timing of percutaneous coronary intervention; Assigned to Arm(s): Early Intervention, Immediate Intervention, Selective invasive angiography
D: Arm Label: Early Coronary Intervention; Type: OTHER; Interventions: Procedure: Early Coronary Intervention | Arm Label: Delayed Coronary Intervention; Type: OTHER; Interventions: Procedure: Delayed Coronary Intervention | Intervention Type: PROCEDURE; Name: Early Coronary Intervention; Assigned to Arm(s): Early Coronary Intervention | Intervention Type: PROCEDURE; Name: Delayed Coronary Intervention; Assigned to Arm(s): Delayed Coronary Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Brief Summary: The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.


Options:
A: Arm Label: Bendamustine + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Venetoclax + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Bendamustine + Rituximab Crossover Substudy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Arm Label: Venetoclax + Rituximab Re-Treatment; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Rituximab | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine + Rituximab, Bendamustine + Rituximab Crossover Substudy, Venetoclax + Rituximab, Venetoclax + Rituximab Re-Treatment
B: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
C: Arm Label: Bendamustine + GA101 + CAL-101; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: CAL-101 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: CAL-101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101
D: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Fludarabine, Biological: Rituximab | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Brief Summary: The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.


Options:
A: Arm Label: Active Comparator 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 500mg, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Active Comparator 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 1000mg, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Ofatumumab 500mg; Assigned to Arm(s): Active Comparator 1 | Intervention Type: DRUG; Name: Ofatumumab 1000mg; Assigned to Arm(s): Active Comparator 2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Active Comparator 1, Active Comparator 2 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Active Comparator 1, Active Comparator 2
B: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
C: Arm Label: ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: ofatumumab | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): ofatumumab
D: Arm Label: ofatumumab + chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: chlorambucil, tablets, Drug: ofatumumab (GSK1841157) infusion | Arm Label: chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil, tablets | Intervention Type: DRUG; Name: chlorambucil, tablets; Assigned to Arm(s): chlorambucil, ofatumumab + chlorambucil | Intervention Type: DRUG; Name: ofatumumab (GSK1841157) infusion; Assigned to Arm(s): ofatumumab + chlorambucil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry for Prevention of Bacteriuria in Pregnancy
Brief Summary: The purpose of this study is to determine the amount of cranberry juice that is most effective in preventing a condition in pregnant women that often leads to urinary tract infections (UTIs).


Options:
A: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
B: Arm Label: Cranberry Juice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice, Dietary Supplement: Cranberry Juice | Arm Label: Placebo cranberry juice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo cranberry juice | Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): Cranberry Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry Juice; Assigned to Arm(s): Cranberry Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo cranberry juice; Assigned to Arm(s): Placebo cranberry juice
C: Arm Label: Cranberry capsule; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cranberry capsules | Arm Label: Placebo capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry capsules; Assigned to Arm(s): Cranberry capsule, Placebo capsule
D: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry for Prevention of Bacteriuria in Pregnancy
Brief Summary: The purpose of this study is to determine the amount of cranberry juice that is most effective in preventing a condition in pregnant women that often leads to urinary tract infections (UTIs).


Options:
A: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
B: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
C: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry for Prevention of Bacteriuria in Pregnancy
Brief Summary: The purpose of this study is to determine the amount of cranberry juice that is most effective in preventing a condition in pregnant women that often leads to urinary tract infections (UTIs).


Options:
A: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose
B: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
C: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Brief Summary: The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.


Options:
A: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): N/A
D: Arm Label: Myocardial fibrosis, outcomes; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Brief Summary: The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.


Options:
A: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
B: Arm Label: Finerenone(BAY94-8862)[2.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[7.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[10mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[15mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Eplerenone [25 mg] + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Inspra (eplerenone) | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Eplerenone [25 mg] + Placebo, Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Inspra (eplerenone); Assigned to Arm(s): Eplerenone [25 mg] + Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone, Drug: Standard care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard care | Arm Label: Observational; Type: OTHER; Interventions: Drug: Standard care | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard care; Assigned to Arm(s): Observational, Placebo, Spironolactone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy
Brief Summary: The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids. Patients will receive either infliximab (a drug used to treat autoimmune diseases) or azathioprine (an immunosuppressant or drug used to suppress the immune system) or a combination of both for up to 34 weeks. This research study will involve approximately 500 patients. The main study involves up to 34 weeks (approximately 8 months). A study extension of an additional 20 weeks (approximately 5 months) is optional for patients who successfully complete the main study. A country-specific study extension of open label infliximab treatment for an additional 1 year is optional for patients who successfully complete the main study extension.


Options:
A: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
B: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducational programme, Other: Standard care | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Intervention Type: BEHAVIORAL; Name: Psychoeducational programme; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Control group, Intervention group
C: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, sugar pill | Arm Label: Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone | Intervention Type: OTHER; Name: Placebo, sugar pill; Assigned to Arm(s): Sugar pill
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sargramostim (Leukine) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sargramostim (Leukine); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy
Brief Summary: The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids. Patients will receive either infliximab (a drug used to treat autoimmune diseases) or azathioprine (an immunosuppressant or drug used to suppress the immune system) or a combination of both for up to 34 weeks. This research study will involve approximately 500 patients. The main study involves up to 34 weeks (approximately 8 months). A study extension of an additional 20 weeks (approximately 5 months) is optional for patients who successfully complete the main study. A country-specific study extension of open label infliximab treatment for an additional 1 year is optional for patients who successfully complete the main study extension.


Options:
A: Arm Label: PRECISION dosing; Type: EXPERIMENTAL; Interventions: Drug: PRECISION dosing Infliximab | Arm Label: Conventional dosing of Infliximab; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PRECISION dosing Infliximab; Assigned to Arm(s): PRECISION dosing
B: Arm Label: CT-P13; Type: EXPERIMENTAL; Interventions: Drug: Biosimilar infliximab | Arm Label: INX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Innovator infliximab | Intervention Type: DRUG; Name: Innovator infliximab; Assigned to Arm(s): INX | Intervention Type: DRUG; Name: Biosimilar infliximab; Assigned to Arm(s): CT-P13
C: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2

Answer: C